ERNAW — Ernexa Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 748592 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -5,590,000 | -5,506,000 | 10,543,000 | 9,177,000 | 3,684,000 |
| Sep 2025 | 0 | 0 | -1,993,000 | -1,240,000 | 6,172,000 | 3,047,000 | 2,602,000 |
| Jun 2025 | 0 | 0 | -2,501,000 | -3,139,000 | 7,584,000 | 4,315,000 | 3,140,000 |
| Mar 2025 | 0 | 0 | -2,730,000 | -8,202,000 | 5,059,000 | 1,918,000 | 11,009,000 |
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,319,000 | -14,084,000 | 5,834,000 | 3,433,000 | 2,401,000 | — |
| Dec 2024 | 582,000 | -15,674,000 | -44,539,000 | 5,269,000 | 3,568,000 | 1,701,000 | — |
| Dec 2023 | 68,000 | -21,135,000 | -21,668,000 | 49,132,000 | 46,899,000 | 2,233,000 | — |
| Dec 2022 | 0 | -33,217,000 | -24,579,000 | 22,279,000 | 10,172,000 | 12,107,000 | — |
| Dec 2021 | 0 | -113,552,000 | -122,306,000 | 32,429,000 | 25,927,000 | 6,502,000 | — |
| Dec 2020 | 5,800,000 | -6,309,000 | -4,415,000 | 3,745,000 | 2,894,000 | 851,000 | — |
| Dec 2019 | 19,806,000 | -1,762,000 | -2,047,000 | 14,125,000 | 9,034,000 | 5,091,000 | — |
| Dec 2018 | 23,335,000 | 203,000 | -259,000 | 14,864,000 | 7,947,000 | 6,917,000 | — |
| Dec 2017 | 21,274,000 | -1,402,000 | -1,077,000 | 16,570,000 | 11,034,000 | 5,536,000 | — |
| Dec 2016 | 22,312,000 | -2,278,000 | -2,923,000 | 16,695,000 | 12,627,000 | 4,068,000 | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-11,388,000
OpCashFlow TTM
—
Assets (Latest)
$10,543,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.04T | $1169.60 | — |
| JNJ | JOHNSON & JOHNSON | $618.09B | $256.48 | — |
| ABBV | AbbVie Inc. | $481.40B | $272.42 | — |
| MRK | Merck & Co., Inc. | $351.28B | $142.38 | — |
| NVS | NOVARTIS AG | $272.01B | $143.11 | — |
News headlines (Yahoo Finance, 1h cache)
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
2026-07-15 11:50 · Yahoo
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
2026-07-14 13:01 · Yahoo
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
2026-07-24 13:20 · Yahoo
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
2026-06-17 12:47 · Yahoo
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
2026-05-20 12:31 · Yahoo
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
2026-10-06 12:55 · Yahoo
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
2026-10-01 13:20 · Yahoo
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
2026-09-30 12:32 · Yahoo
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
2026-09-29 13:15 · Yahoo
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
2026-09-17 12:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.